Axitinib

Axitinib is a prescription medication used to treat advanced kidney cancer. It is a type of targeted therapy known as a tyrosine kinase inhibitor (TKI), which works by blocking the action of certain proteins that help cancer cells grow. Axitinib is taken orally, usually once a day. Common side effects include fatigue, high blood pressure, nausea, and diarrhea.

Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor medication developed by Pfizer. It is primarily used to treat advanced renal cell carcinoma (a type of kidney cancer) in adults who have not responded well to other medications.

Here's a summary of how Axitinib works:

  • Type of drug: Kinase inhibitor
  • Mechanism of action: Blocks the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
  • Conditions treated: Advanced renal cell carcinoma (RCC)

It is important to note that I am not a medical professional and this information should not be taken as medical advice. Please consult with your doctor to discuss if Axitinib is the right treatment for you.

 

Anatomical Therapeutic Chemical Classification
L - Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L01E - Protein kinase inhibitors
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
External Links